Sarepta Therapeutics (SRPT)

Sarepta Therapeutics Stock Analysis & Ratings

SRPT Stock Chart & Stats

Day’s Range$68.33 - $71.19
52-Week Range$61.28 - $101.24
Previous Close$69.22
Average Volume (3M)857.09K
Market Cap$6.22B
P/E Ratio-16.3
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score3
EPS (TTM)-4.25



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $61.28 and its highest was $101.24 in the past 12 months.
    What is Sarepta Therapeutics’s market cap?
    Sarepta Therapeutics’s market cap is $6.22B.
      What is Sarepta Therapeutics’s price target?
      The average price target for Sarepta Therapeutics is $119.42. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $155.00 ,the lowest forecast is $74.00. The average price target represents 67.89% Increase from the current price of $71.13.
        What do analysts say about Sarepta Therapeutics?
        Sarepta Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
          When is Sarepta Therapeutics’s upcoming earnings report date?
          Sarepta Therapeutics’s upcoming earnings report date is Aug 10, 2022 which is in 82 days.
            How were Sarepta Therapeutics’s earnings last quarter?
            Sarepta Therapeutics released its earnings results on May 04, 2022. The company reported -$1.2 earnings per share for the quarter, beating the consensus estimate of -$1.313 by $0.113.
              Is Sarepta Therapeutics overvalued?
              According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
                Does Sarepta Therapeutics pay dividends?
                Sarepta Therapeutics does not currently pay dividends.
                What is Sarepta Therapeutics’s EPS estimate?
                Sarepta Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Sarepta Therapeutics have?
                Sarepta Therapeutics has 87,500,000 shares outstanding.
                  What happened to Sarepta Therapeutics’s price movement after its last earnings report?
                  Sarepta Therapeutics reported an EPS of -$1.2 in its last earnings report, beating expectations of -$1.313. Following the earnings report the stock price went down -1.457%.
                    Which hedge fund is a major shareholder of Sarepta Therapeutics?
                    Among the largest hedge funds holding Sarepta Therapeutics’s share is Sands Capital Management LLC. It holds Sarepta Therapeutics’s shares valued at 374M.


                      Sarepta Therapeutics Stock Analysis

                      Smart Score
                      Price Target
                      ▲(67.89% Upside)
                      Strong Buy
                      The Sarepta Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Sarepta Therapeutics

                      Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

                      Similar Stocks
                      Price & Change
                      PTC Therapeutics
                      Summit Therapeutics
                      Alnylam Pharma
                      Astria Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis